Efficacy and safety of deep hyperthermia combined with tislelizumab and chemotherapy in the treatment of advanced squamous non-small-cell lung cancer: a single-center retrospective study - Scorecard - MDSpire
Advertisement
Efficacy and safety of deep hyperthermia combined with tislelizumab and chemotherapy in the treatment of advanced squamous non-small-cell lung cancer: a single-center retrospective study
Clinical Scorecard: Assessment of the Safety and Effectiveness of Deep Hyperthermia in Combination with Tislelizumab and Chemotherapy for Advanced Squamous Non-Small-Cell Lung Cancer: A Retrospective Analysis from a Single Center
At a Glance
Category
Detail
Condition
Advanced Squamous Non-Small-Cell Lung Cancer (NSCLC)
Key Mechanisms
Deep hyperthermia enhances tumor cell sensitivity to treatment and boosts immune response.
Target Population
Patients with advanced squamous NSCLC, specifically those with PD-L1 TPS expression level less than 50%.
Care Setting
Oncology department in a hospital setting.
Key Highlights
ORR in experimental group: 66.0% vs. 46.0% in control group (P = 0.044).
DCR in experimental group: 86.0% vs. 84.0% in control group.
No significant difference in TRAEs between groups (P > 0.05).
Median PFS and OS showed no statistically significant difference (P = 0.647; P = 0.370).
Combination therapy is safe and effective for advanced squamous NSCLC.
Guideline-Based Recommendations
Diagnosis
Histopathological or cytological confirmation of inoperable squamous cell carcinoma.
AJCC 8th edition stage IV lung cancer.
Management
Combination of deep hyperthermia, tislelizumab, and chemotherapy as initial therapy.
Monitoring & Follow-up
Regular assessment of treatment response and adverse events.
Risks
Exclusion of patients with severe organic diseases or immunodeficiency disorders.
Patient & Prescribing Data
100 patients with advanced squamous NSCLC, median age 66 years.
Deep hyperthermia combined with tislelizumab and chemotherapy shows improved ORR without increased adverse events.
Clinical Best Practices
Ensure informed consent and eligibility criteria are met.
Monitor patient response and adjust treatment as necessary.
Consider patient history, including smoking status and organ function.
